Association of albumin-corrected anion gap with all-cause and cardiovascular mortality in overactive bladder patients Authors: Shiwei Lin, Xiaofang Chen Published: 2025 ABSTRACT AbstractOveractive bladder (OAB) is a symptom syndrome characterized by urgency, often accompanied by frequency and nocturia. It significantly impacts patients’ quality of life and imposes a substantial economic burden. The albumin-corrected anion gap (ACAG), an important indicator reflecting the body’s acid–base balance and electrolyte disturbances, has predictive value in various chronic diseases. However, its association with the prognosis of OAB patients has not been adequately studied. This study aims to explore the relationship between ACAG levels and all-cause mortality and cardiovascular mortality in OAB patients. A total of 6592 OAB patients (representing 31,072,714 individuals in the U.S. population) from the 2005–2018 NHANES database were included based on strict inclusion criteria. The relationship between ACAG and mortality risk was analyzed using a multivariable-adjusted Cox proportional hazards regression model, with non-linear associations assessed using restricted cubic splines (RCS). Additionally, Kaplan–Meier survival analysis and subgroup analyses were conducted to evaluate the association between ACAG and mortality risk. During an average follow-up of 79.5 months, 1332 all-cause deaths and 352 cardiovascular deaths occurred. In the fully adjusted model, each 1-unit increase in ACAG was associated with an 11% higher risk of all-cause mortality (HR = 1.11, 95% CI 1.06–1.15) and an 8% higher risk of cardiovascular mortality (HR = 1.08, 95% CI 1.01–1.16). Analysis based on ACAG tertiles revealed that, compared to the lowest tertile, the highest tertile was associated with an 65% increased risk of all-cause mortality (HR = 1.65, 95% CI 1.33–2.04) and a 43% increased risk of cardiovascular mortality (HR = 1.43, 95% CI 1.22–1.63), showing a significant dose–response relationship (all-cause mortality P for trend < 0.001; cardiovascular mortality P for trend = 0.028). RCS analysis indicated a linear positive correlation between ACAG and mortality risk. Elevated ACAG levels are significantly associated with both all-cause and cardiovascular mortality in OAB patients, with this association being consistent across various subgroups. This study provides the first evidence of the potential value of ACAG as a prognostic biomarker for OAB patients, offering new insights for clinical risk stratification and personalized treatment strategies.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-27920-y.Keywords: Overactive bladder, Albumin-corrected anion gap, All-cause mortality, Cardiovascular mortality, NHANESSubject terms: Biomarkers, Prognostic markers, Nephrology Introduction According to the International Continence Society, overactive bladder (OAB) is a symptom syndrome characterized by urgency, often accompanied by frequency and nocturia, with or without urgency urinary incontinence, and without urinary tract infection or other obvious pathology1. OAB is a highly prevalent urological disorder worldwide, with global prevalence estimates ranging from approximately 11.8% to 16.6%, varying across regions and populations2. OAB is a common and distressing chronic condition that severely impacts quality of life and imposes a substantial economic burden3. It is estimated that OAB results in billions of dollars in losses to healthcare budgets and the overall economy of developed countries4. Given the aging population and the increasing prevalence of OAB with age, the economic burden of OAB is expected to rise. Additionally, OAB adversely affects professional and work productivity5,6. However, the risk factors and pathophysiology of OAB remain incompletely understood. Numerous studies have indicated that OAB may be associated with various risk factors, including body mass index (BMI)7, diet8, nicotine9, alcohol consumption10, physical activity11, sleep disorders12, diabetes13, and hypertension14. Considering the significant impact of OAB on individuals and society, identifying modifiable risk factors and implementing early interventions is crucial. The anion gap (AG) is an important indicator of the body’s acid–base balance and electrolyte disturbances, while the albumin-corrected anion gap (ACAG) adjusts the AG for serum albumin levels15. ACAG is primarily used to more accurately reflect the ion balance and predict patient prognosis, providing clinical value by early identification of high-risk patients and guiding individualized treatment and intervention strategies. Patients with OAB often present with autonomic dysfunction and metabolic abnormalities, which may be associated with ACAG levels through alterations in acid–base balance. Evidence has shown that the prevalence of metabolic syndrome is significantly higher in individuals with OAB compared to the general population16. Previous studies have confirmed that elevated ACAG may be associated with the development and poor prognosis of various chronic diseases, such as kidney disease17, heart failure18, and diabetes19, among others. However, the relationship between ACAG and prognosis in OAB patients remains insufficiently explored, particularly its impact on all-cause and cardiovascular mortality. Given that ACAG is a simple and readily available clinical indicator, further investigation into its relationship with OAB prognosis is of significant clinical importance. This study, based on cohort data from NHANES, aims to explore the association between ACAG levels and all-cause and cardiovascular mortality in OAB patients and evaluate the impact of different ACAG levels on prognosis. Through a large-sample, long-term follow-up cohort study design, we aim to clarify the role of ACAG in the prognosis assessment of OAB patients and provide new insights for the clinical management of OAB. The results of this study will contribute to the refinement of prognosis risk assessment models for OAB patients, offering a reference for early identification of high-risk patients and optimization of treatment strategies, ultimately improving the long-term prognosis of OAB patients. Methods Study participants The National Health and Nutrition Examination Survey (NHANES), initiated in the 1960s, has become a pivotal nationwide health and nutrition survey under the oversight of the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC). Since 1999, NHANES has evolved into a continuous survey program, conducting comprehensive data collection every two years. NHANES employs a multi-stage approach, including detailed questionnaires, professional physical exams, and extensive laboratory tests, covering a wide range of data, including demographic characteristics, dietary intake, physical metrics, and biochemical indicators. This systematic data collection enables NHANES to provide an in-depth reflection of the health and nutrition status of the U.S. population and serves as a scientific foundation for policymaking. Notably, NHANES adheres strictly to ethical guidelines, requiring informed consent from participants. Its findings are publicly accessible, promoting transparency and public engagement. This large-scale health survey has proven invaluable for researchers and public health policymakers alike, supporting disease prevention and national health improvement initiatives. NHANES employs a complex, multistage probability sampling design to obtain a nationally representative sample of the U.S. population. In the present study, we applied appropriate inclusion and exclusion criteria to derive the analytic sample. Specifically, we analyzed NHANES data from 2005 to 2018, with an initial sample size of 70,190 participants. The screening process followed three key steps: First, OAB (overactive bladder) patients were identified, and 62,943 non-OAB individuals were excluded, leaving 7247 OAB patients. Second, participants under 20 years old and pregnant women were excluded, reducing the sample to 7019 individuals. Finally, participants with missing data on ACAG or mortality were excluded, resulting in a final sample size of 6592 individuals (Fig. 1). This meticulous screening ensured homogeneity among the study subjects and data completeness, minimizing potential confounding factors and enhancing the scientific and practical value of the study findings. A flow diagram of eligible participant selection in the National Health and Nutrition. Abbreviation: ACAG, albumin-corrected anion gap; OAB, overactive bladder Mortality information for NHANES participants was obtained through the National Death Index (NDI) up to December 31, 2018. The label “missing mortality data” refers to participants whose vital status could not be ascertained via the NDI, which may have resulted from data mismatches, loss to follow-up, or other technical reasons. To ensure data quality, these participants were excluded from the final analysis. OAB assessment The accurate assessment and diagnosis of overactive bladder (OAB) require a systematic approach to symptom evaluation. According to the definition, urgency incontinence and nocturia are core symptoms crucial for diagnosing OAB. To ensure standardized evaluation, the research team used three key NHANES questions (KIQ044, KIQ450, and KIQ480) to assess urinary incontinence and nocturia20: (1) In the past year, have you experienced involuntary urine leakage with urgency or pressure, making it difficult to reach the bathroom on time? (2) How often did this occur? (3) In the past month, how many times did you wake up to urinate between sleep and morning? The Overactive Bladder Symptom Score (OABSS) was then used to quantify OAB symptoms21, with scoring criteria detailed in Table S1. The OABSS score is the sum of scores from urgency incontinence and nocturia. Participants with a total score of 3 or higher were considered to have OAB. Measurement of ACAG The anion gap (AG) reflects the levels of unmeasured anions (e.g., lactate, ketones) in the body and is commonly used in diagnosing metabolic acidosis. However, albumin, a major serum anion, significantly affects AG values. Albumin-corrected anion gap (ACAG) adjusts for albumin levels to provide a more accurate reflection of ionic balance and prognosis. The ACAG formula is: where AG (mmol/L) = Na (mmol/L) − (Cl (mmol/L) + HCO₃ (mmol/L))17. The normal clinical reference range for ACAG is generally 12–20 mmol/L22 . In this study, to explore the dose–response relationship between ACAG and mortality risk, participants were divided into tertiles based on ACAG levels: T1 (< 14.5 mmol/L), T2 (14.5–16.6 mmol/L), and T3 (> 16.6 mmol/L). It should be noted that T1 roughly corresponds to the lower end of the normal range, T2 primarily covers the upper portion of the normal range, and T3 includes values exceeding the normal upper limit. This tertile-based grouping facilitates statistical analysis and helps identify potential risk increases that may already exist even when ACAG levels remain within the conventional normal range but approach the upper limit. Outcome ascertainment The primary outcomes of this study were all-cause mortality and cardiovascular mortality. Mortality data as of December 31, 2019, were obtained from the National Death Index (NDI), which follows strict information collection standards. The NDI data includes essential information such as name, Social Security number, race/ethnicity, date of birth, marital status, gender, and residence. Causes of death were classified and coded according to the International Classification of Diseases, 10th edition (ICD-10), to ensure accuracy and international comparability. Cardiovascular death was defined using ICD-10 codes I00-I09, I11, I13, and I20-I51. Covariates The covariates in this study included age, gender, race, marital status, education level, poverty-income ratio (PIR), obesity, smoking, alcohol consumption, hypertension, diabetes, and hyperlipidemia. More details on these covariates can be found in Table S2. Statistical analysis All statistical analyses considered NHANES’ complex sampling design and weights. Continuous variables were presented as means ± standard deviations (mean ± SD), and inter-group comparisons were made using weighted Student’s t-tests. Categorical variables were expressed as weighted frequencies and percentages, with between-group comparisons conducted using weighted chi-square tests. To assess the relationship between ACAG and all-cause mortality as well as cardiovascular mortality, three Cox proportional hazards regression models were constructed: Model 1 was the unadjusted crude model; Model 2 adjusted for demographic factors (age, gender, education level, marital status, PIR, and race); Model 3 further adjusted for clinical factors (obesity, smoking, alcohol consumption, hypertension, diabetes, and hyperlipidemia). Results were presented as hazard ratios (HR) with 95% confidence intervals (95% CI). ACAG was analyzed as both a continuous variable and as categorized by tertiles (T1-T3), with trend tests (P for trend) performed. Additionally, restricted cubic splines (RCS) were used to visualize the non-linear relationship between ACAG and mortality risk. Kaplan–Meier survival curves were used to assess survival differences across ACAG levels. Finally, subgroup analyses were conducted to evaluate the association between ACAG and mortality risk in different populations. All statistical tests were two-sided, with P < 0.05 considered statistically significant. All analyses were performed using R (version 4.3.1). Result Characteristics of the participants As shown in Table 1, a total of 6592 participants were included in this study, representing 31,072,714 U.S. adults. Over an average follow-up period of 79.5 months, there were 1332 deaths from all causes and 352 cardiovascular deaths. Compared to the survival group, the deceased group was more likely to be older (> 60 years, 81% vs. 42%), male (46% vs. 36%), and non-Hispanic White (78% vs. 63%), with a higher prevalence of hypertension (76% vs. 56%) and diabetes (40% vs. 26%) (all P < 0.001). The mean ACAG was significantly higher in the death group compared to the survival group (15.91 ± 2.25 vs. 15.81 ± 2.60, P = 0.037). Table 1The demographic characteristics of the OAB population in the present study were stratified by survival status, weighted.CharacteristicOverall, N = 31,072,714 (100%)Survivor, N = 25,790,577 (83%)Non-survivor, N = 5,282,137 (17%)P valueNo. of participants in the sample659252601332–Age (%) < 0.001 20–6016,010,224 (52%)15,008,291 (58%)1,001,934 (19%) > 6015,062,489 (48%)10,782,286 (42%)4,280,203 (81%)Sex (%) < 0.001 Female19,248,223 (62%)16,412,439 (64%)2,835,784 (54%) Male11,824,491 (38%)9,378,138 (36%)2,446,352 (46%)Race (%) < 0.001 Non-Hispanic white20,384,520 (66%)16,277,255 (63%)4,107,264 (78%) Non-Hispanic black4,987,947 (16%)4,318,058 (17%)669,890 (13%) Other3,374,360 (11%)3,075,683 (12%)298,677 (5.7%) Mexican American2,325,887 (7.5%)2,119,581 (8.2%)206,306 (3.9%)Married/live with partner (%) < 0.001 No12,909,897 (42%)10,202,447 (40%)2,707,450 (51%) Yes18,149,184 (58%)15,576,932 (60%)2,572,252 (49%)Education level (%) < 0.001 Below high school7,661,206 (25%)5,932,181 (23%)1,729,025 (33%) High school or above23,392,602 (75%)19,846,642 (77%)3,545,960 (67%)PIR (%)0.003 Poor8,168,766 (29%)6,513,738 (28%)1,655,028 (34%) Not poor20,297,745 (71%)17,088,363 (72%)3,209,382 (66%)Obesity (%) < 0.001 No15,546,746 (51%)12,593,324 (49%)2,953,422 (58%) Yes15,080,046 (49%)12,957,202 (51%)2,122,844 (42%)Smoking (%) < 0.001 Never14,979,957 (48%)12,776,355 (50%)2,203,602 (42%) Former9,541,979 (31%)7,533,531 (29%)2,008,447 (38%) Current6,522,587 (21%)5,468,232 (21%)1,054,356 (20%)Drinking (%) < 0.001 Never4,229,718 (14%)3,330,432 (14%)899,286 (17%) Former6,375,506 (22%)4,450,869 (18%)1,924,637 (37%) Mild10,177,667 (34%)8,600,557 (35%)1,577,109 (30%) Moderate4,252,160 (14%)3,858,671 (16%)393,489 (7.6%) Heavy4,492,932 (15%)4,085,698 (17%)407,234 (7.8%)Hypertension (%) < 0.001 No12,571,791 (40%)11,311,225 (44%)1,260,565 (24%) Yes18,498,240 (60%)14,479,352 (56%)4,018,889 (76%)Diabetes (%) < 0.001 No22,373,570 (72%)19,185,206 (74%)3,188,364 (60%) Yes8,699,144 (28%)6,605,371 (26%)2,093,773 (40%)Hyperlipidemia (%)0.15 No6,166,020 (20%)5,218,625 (20%)947,396 (18%) Yes24,906,694 (80%)20,571,952 (80%)4,334,741 (82%)ACAG (mean (SD))15.83 (2.55)15.81 (2.60)15.91 (2.25)0.037ACAG, Tertile (%)0.006 T1(< 14.5 mmol/L)10,240,035 (33%)8,798,052 (34%)1,441,983 (27%) T2(14.5–16.6 mmol/L)10,476,157 (34%)8,474,963 (33%)2,001,193 (38%) T3(> 16.6 mmol/L)10,356,522 (33%)8,517,562 (33%)1,838,960 (35%)Cardiovascular mortality (%)1,383,451 (4.5%)0 (0%)1,383,451 (26%) < 0.001T1–T3: Grouped by Tertile according to ACAG. Mean (SD) for continuous variables: the P value was calculated by the weighted Students T-test. Percentages (weighted N, %) for categorical variables: the P value was calculated by the weighted chi-square test. ACAG, albumin-corrected anion gap; OAB, overactive bladder; PIR, ratio of family income to poverty. Significant values are in bold. The demographic characteristics of the OAB population in the present study were stratified by survival status, weighted. T1–T3: Grouped by Tertile according to ACAG. Mean (SD) for continuous variables: the P value was calculated by the weighted Students T-test. Percentages (weighted N, %) for categorical variables: the P value was calculated by the weighted chi-square test. ACAG, albumin-corrected anion gap; OAB, overactive bladder; PIR, ratio of family income to poverty. Significant values are in bold. Associations of the ACAG with all-cause and cardiovascular mortality As shown in Table 2, in the fully adjusted model (Model 3), every 1-unit increase in ACAG was associated with an 11% increase in all-cause mortality risk (HR = 1.11, 95% CI 1.06–1.15) and an 8% increase in cardiovascular mortality risk (HR = 1.08, 95% CI 1.01–1.16). Grouping by ACAG tertiles revealed that, compared to the T1 group, the T3 group had a 65% higher risk of all-cause mortality (HR = 1.65, 95% CI 1.33–2.04) and a 43% higher risk of cardiovascular mortality (HR = 1.43, 95% CI 1.22–1.63), showing a significant dose–response relationship (all-cause mortality P for trend < 0.001; cardiovascular mortality P for trend = 0.020). Restricted cubic spline analysis showed a linear positive association between ACAG and mortality risk (Fig. 2). Furthermore, Fig. 3 presents Kaplan–Meier survival curves showing significant differences in all-cause and cardiovascular mortality between the three groups. Participants in the highest ACAG tertile (T3) (ACAG > 16.6 mmol/L) had the highest mortality rate, while those in the lowest tertile (T1) had the lowest mortality rate (log-rank p < 0.001). Table 2HRs (95% CIs) for All-cause mortality and Cardiovascular mortality according to ACAG in the OAB population.ACAGModel 1[HR (95% CI)]p-valueModel 2[HR (95% CI)]p-valueModel 3[HR (95% CI)]p-valueAll-cause mortality Continuous1.17(1.13,1.21) < 0.0011.13(1.10,1.17) < 0.0011.11(1.06,1.15) < 0.001 Tertile T11 (ref.)1 (ref.)1 (ref.) T21.47(1.19,1.82)0.0011.30(1.05,1.60)0.0201.20(0.97,1.48)0.090 T32.44(2.02,2.95) < 0.0011.96(1.62,2.36) < 0.0011.65(1.33,2.04) < 0.001 P for trend < 0.001 < 0.001 < 0.001Cardiovascular mortality Continuous1.17(1.10,1.24) < 0.0011.12(1.05, 1.20) < 0.0011.08(1.01,1.16)0.032 Tertile T11 (ref.)1 (ref.)1 (ref.) T21.47(1.02,2.14)0.0401.27(0.89, 1.79)0.1801.14(0.79,1.63)0.480 T32.42(1.63,3.60) < 0.0011.83(1.23, 2.71)0.0031.43(1.22,1.63)0.023 P for trend < 0.0010.0030.028Model 1: No covariates were adjusted. Model 2: age, sex, education level, marital status, PIR, and race were adjusted. Model 3: age, sex, education level, marital status, PIR, race, obesity, smoking, drinking, hypertension, diabetes, chronic kidney disease, and Hyperlipidemia were adjusted. ACAG, albumin-corrected anion gap; OAB, overactive bladder; PIR, Ratio of family income to poverty; HR, hazard ratio; CI, confidence interval. HRs (95% CIs) for All-cause mortality and Cardiovascular mortality according to ACAG in the OAB population. Model 1: No covariates were adjusted. Model 2: age, sex, education level, marital status, PIR, and race were adjusted. Model 3: age, sex, education level, marital status, PIR, race, obesity, smoking, drinking, hypertension, diabetes, chronic kidney disease, and Hyperlipidemia were adjusted. ACAG, albumin-corrected anion gap; OAB, overactive bladder; PIR, Ratio of family income to poverty; HR, hazard ratio; CI, confidence interval. The association of ACAG with All-cause (A) and Cardiovascular mortality (B) among OAB visualized by restricted cubic spline. HR (solid lines) and 95% confidence levels (shaded areas) were adjusted for age, sex, education level, marital status, PIR, race, obesity, smoking, drinking, hypertension, diabetes, and Hyperlipidemia. Abbreviation: ACAG, albumin-corrected anion gap; PIR, ratio of family income to poverty; HR, hazard ratio; CI, confidence interval. Kaplan–Meier analyses for mortality among the three groups. T1–T3, Tertiles 1–3; ACAG, albumin-corrected anion gap. (A) All-cause mortality; (B) Cardiovascular mortality. Subgroup analysis A subgroup analysis was conducted to assess the robustness of the association between ACAG and mortality across different subgroups of OAB patients. The results (shown in Fig. 4) indicate that the positive association between ACAG and mortality risk was consistent across different subgroups. However, none of the interaction tests reached statistical significance (P for interaction > 0.05 in all subgroups). Subgroup analysis between ACAG and mortality. (A), ACAG—All-cause mortality; (B), ACAG—Cardiovascular mortality. HRs were calculated per 1-unit increase in ACAG. Analyses were adjusted for age, sex, education level, marital status, PIR, race, obesity, smoking, drinking, hypertension, diabetes, and Hyperlipidemia. Discussion This study is the first to explore the association between anion gap corrected for albumin (ACAG) and mortality risk in patients with overactive bladder (OAB). In this large-scale cohort study based on the NHANES database, we found that higher ACAG levels were significantly associated with all-cause mortality and cardiovascular mortality in OAB patients. This association was consistently observed across different population subgroups, underscoring its clinical relevance. The relationship between ACAG levels and mortality has been well-established in several studies, with ACAG proving to be a reliable prognostic marker. For instance, an analysis of 1783 patients with acute myocardial infarction (AMI) found that elevated serum ACAG (≥ 20 mmol/L) was an independent risk factor for both short- and long-term mortality in critically ill AMI patients23. A study on 710 patients with aneurysmal subarachnoid hemorrhage (aSAH) using an albumin-corrected anion gap prognostic model demonstrated that ACAG was an effective prognostic indicator for aSAH patients. aSAH can cause acidosis through various mechanisms, including cerebral hypoxia, accumulation of acidic metabolites, and electrolyte imbalances (e.g., hypokalemia and hypocalcemia). ACAG levels were found to be significantly positively correlated with mortality24. Moreover, a study examining the relationship between ACAG and short-term outcomes in patients with cardiogenic shock showed that patients with high ACAG values had significantly higher short-term all-cause mortality, including ICU, in-hospital, and 28-day mortality rates. Another study reported that in asthmatic patients admitted to the ICU within 30 days, higher ACAG scores were associated with increased mortality risk. Elevated ACAG levels were also found to be independently correlated with higher in-hospital mortality in ICU trauma patients25. ACAG has been identified as a reliable predictor of 30-day mortality, with better predictive performance than AG26. Zhang et al.27 reported that, during a one-year follow-up of patients with acute coronary syndrome, a serum anion gap (AG) ≥ 11.15 mmol/L was associated with cardiovascular events. Additionally, AG has been identified as an independent predictor of in-hospital mortality in patients with acute ischemic stroke28. Furthermore, a study investigating AG and mortality in patients with cardiac arrest found that those with higher AG levels had lower in-hospital survival rates compared to patients with lower AG levels29. These findings collectively support the idea that elevated ACAG may increase mortality risk through mechanisms such as exacerbating metabolic acidosis, promoting inflammation, and accelerating vascular damage. This study extends these findings to the long-term mortality in chronic disease patients (OAB), further supporting the potential of ACAG as a cross-disease metabolic biomarker. The mechanisms linking elevated ACAG to mortality are multifactorial. Patients with higher ACAG levels are often accompanied by more severe metabolic abnormalities (such as diabetes, hypertension, and dyslipidemia), which may jointly promote disease progression and increase mortality risk. Elevated ACAG levels reflect a greater degree of metabolic acidosis, which exacerbates insulin resistance, promotes inflammation, and leads to endothelial dysfunction, thereby increasing the risk of cardiovascular disease and other complications19. A prospective, population-based study involving 1191 healthy adults in China from 2006 to 2012 found that higher AG levels were associated with an increased likelihood of glucose metabolism abnormalities30. AG and acid–base balance are crucial for maintaining normal physiological conditions and are related to the occurrence and prognosis of various diseases. Our study found that in OAB patients with elevated ACAG levels, the proportions of diabetes, hypertension, and obesity were significantly higher. These metabolic abnormalities are important risk factors for cardiovascular disease and all-cause mortality. OAB is a common chronic condition closely associated with various metabolic diseases. Metabolic syndrome, including obesity, dyslipidemia, glucose abnormalities, and hypertension, has been shown to play a key role in OAB16. Elevated ACAG reflects the accumulation of unmeasured anions (such as lactate, sulfate, and ketones), suggesting a state of metabolic acidosis. Metabolic acidosis activates inflammatory pathways such as NF-κB, leading to the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)31. These inflammatory mediators not only damage endothelial function but also increase the risk of cardiovascular events by promoting plaque instability and myocardial fibrosis23. Moreover, acidosis can directly impair myocardial contractility, leading to arrhythmias and heart failure. Studies have shown that ACAG is positively correlated with inflammatory markers (such as C-reactive protein) in heart failure patients18, indicating that ACAG, when corrected, can more sensitively reflect lactate levels (a metabolic product of inflammation and hypoxia). Metabolic acidosis may also affect bladder function by impacting the autonomic nervous system (ANS). The ANS plays a critical role in regulating bladder function, including the initiation and inhibition of micturition reflexes. Furthermore, metabolic acidosis may influence the synthesis and release of neurotransmitters, thereby affecting bladder sensory nerve signaling and detrusor muscle function32. In a state of acidosis, nerve conduction and muscle contraction may be impaired, leading to overactive detrusor or avoiding dysfunction. In OAB patients, long-term bladder overactivity may be associated with autonomic dysfunction, further exacerbating systemic microcirculation disorders and hypoxia, thus forming a vicious cycle of acidosis and inflammation. Albumin is the major protein in human plasma, and low albumin levels are associated with increased mortality and acute coronary disease risk33. Albumin is not only a regulator of acid–base balance but also has antioxidant and anti-inflammatory functions34. As the primary plasma protein, albumin scavenges reactive oxygen species (ROS) through its thiol (-SH) groups and inhibits lipid peroxidation by binding to transition metal ions35. Albumin serves as the basis for calculating ACAG, and hypoalbuminemia leads to elevated ACAG while reducing the body’s ability to scavenge free radicals, thus exacerbating oxidative stress. Oxidative stress accelerates arteriosclerosis and myocardial apoptosis through lipid peroxidation and DNA damage36. Furthermore, albumin can bind and transport inflammatory mediators, inhibiting the production and release of inflammatory cytokines, thus mitigating inflammation37. This anti-inflammatory action is crucial for the onset and progression of cardiovascular diseases. OAB patients often experience chronic inflammation and oxidative stress, and hypoalbuminemia, which reduces antioxidant capacity, exacerbates oxidative stress, further worsening bladder inflammation and detrusor dysfunction. Hypoalbuminemia itself is a marker of malnutrition and chronic disease, and OAB patients (especially the elderly) often have decreased albumin levels due to limited activity, drug side effects (such as appetite suppression from anticholinergic medications), or comorbidities (such as diabetes). This nutritional state may further impair bladder function and exacerbate OAB symptoms. Therefore, maintaining appropriate albumin levels is crucial for regulating ACAG, which may help reduce the risk of OAB. ACAG elevation is an important metabolic indicator that directly reflects disturbances in key electrolytes. Its calculation formula includes key electrolyte ions, and elevated ACAG suggests complex imbalances. Electrolyte imbalances may indirectly affect bladder function by altering the physiological processes of nerve conduction and muscle contraction. Research has indicated that electrolyte abnormalities may alter the electrophysiological properties of the atria, thereby promoting the occurrence and maintenance of atrial fibrillation, ultimately worsening prognosis and increasing cardiovascular mortality risk38. In OAB patients, electrolyte imbalances also play an important role. Changes in the concentration gradients of sodium and potassium ions affect the generation and conduction of action potentials, disrupting the normal function of sensory and motor nerves in the bladder39. This change may lead to bladder hypersensitivity and increased voiding reflexes, aggravating urgency and frequency symptoms. Abnormal chloride ion transport can affect the osmotic pressure of interstitial fluids, leading to epithelial cell edema and increased permeability40. This change makes irritants in the urine more likely to contact sensory nerve endings, increasing bladder sensitivity. Electrolyte disturbances can trigger local bladder inflammatory responses, promoting the release of inflammatory mediators (such as IL-6, TNF-α), which can directly stimulate bladder sensory nerves, increasing the sensitivity of C-fibers41, leading to overactive bladder activity. This may also cause bladder wall remodeling and fibrosis, further exacerbating OAB symptoms. However, this study has some inherent limitations. First, as an observational study, it cannot establish a causal relationship between ACAG and mortality. Second, the study was based solely on a U.S. population, and regional and racial differences may limit the generalizability of the results. Furthermore, as ACAG is a dynamic marker influenced by fluctuations in albumin and electrolyte levels, a single baseline measurement may not fully represent an individual’s long-term metabolic or acid–base status. In our study, there was a temporal gap between the assessment of ACAG and the occurrence of mortality events for some participants. This gap could potentially attenuate or bias the observed associations. Therefore, the results should be interpreted with caution, and future studies with repeated ACAG measurements over time are warranted to confirm the stability of these associations and better reflect longitudinal physiological changes. It also did not delve into the specific pathophysiological mechanisms underlying the increased mortality risk in OAB patients associated with elevated ACAG. Additionally, although mortality outcomes in NHANES were standardized through linkage with the National Death Index (NDI), thereby enhancing the completeness and reliability of death data, participants with missing mortality or key covariate information were excluded from the analysis. This exclusion may have introduced selection bias, as excluded individuals could differ systematically from those included in terms of baseline characteristics or mortality risk, potentially affecting the generalizability of our findings. Although sampling weights and multivariable adjustments were applied to minimize this bias, it cannot be completely ruled out. Therefore, the findings should be interpreted with caution. Future research could consider employing more advanced statistical methods, such as multiple imputation, to mitigate this potential bias further. Future research could address these limitations in the following ways: 1) Conduct multi-center prospective studies to validate the predictive value of ACAG in different populations and establish standardized clinical threshold values; 2) Explore in-depth the pathophysiological mechanisms linking elevated ACAG to increased mortality in OAB patients, particularly focusing on its potential relationship with cardiovascular events; 3) Conduct dynamic monitoring studies of ACAG to assess its predictive value regarding prognosis, which could guide individualized treatment strategies; 4) Integrate ACAG with other biomarkers and use advanced technologies such as artificial intelligence to develop more comprehensive prognostic models and create user-friendly predictive tools for clinical use. These future studies will help further elucidate the predictive value of ACAG in OAB patients and enhance its clinical applicability. The findings of this study have significant clinical implications. ACAG, as a routine laboratory measure, can be obtained without additional cost, making it an ideal clinical prognostic tool. Our results indicate that elevated ACAG levels, particularly > 16.6 mmol/L, are significantly associated with all-cause and cardiovascular mortality in OAB patients, providing clinicians with a simple and effective risk assessment marker. Based on these findings, we recommend incorporating ACAG measurement into the standard evaluation of OAB patients. For patients with high ACAG levels, this could include more frequent follow-up, intensified cardiovascular risk management, targeted interventions for metabolic abnormalities, and treatment adjustments according to metabolic status. Such adjustments may involve optimizing nutritional intake (e.g., increasing fruits and vegetables to reduce dietary acid load), timely correction of hypoalbuminemia and electrolyte disturbances, and standardized management of metabolic syndrome and chronic kidney disease to maintain acid–base and systemic homeostasis. In selected populations, individualized alkalinization therapy, such as bicarbonate administration, may be considered, but decisions should be carefully guided by volume status and cardiorenal function. This simple, cost-free marker not only facilitates clinical risk stratification but may also reduce hospitalization rates and healthcare costs and improve patient quality of life by enabling early identification of high-risk individuals and timely interventions. Future research should explore integrating ACAG into comprehensive risk scoring systems to optimize personalized treatment decisions. Conclusion Based on a nationwide sample of OAB patients in the United States, this study found that elevated ACAG levels were significantly associated with both all-cause mortality and cardiovascular mortality. These findings support the clinical application of ACAG as a metabolic disorder and disease prognostic biomarker while also providing direction for future mechanistic research and intervention strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We sincerely appreciate the NHANES database for all the data. Author contributions S.L. contributed to the original draft, Methodology, and Formal analysis. X.C. was involved in Writing—review & editing, Supervision, Project administration, and Investigation. Funding The government, business, or nonprofit sectors provided no specific funding for this research. Data availability The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://wwwn.cdc.gov/nchs/nhanes/. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate The research involving humans was approved by the Research Ethics Review Board of the National Center for Health Statistics. The studies were carried out following local legislative and institutional requirements. The participants provided informed written consent to participate in this study. Consent for publication All participants gave informed consent for publication. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://wwwn.cdc.gov/nchs/nhanes/.